# OnCo record nct05466149 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05466149/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05466149", "NCT05466149" ;
  schema:name "Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion"@en ;
  schema:description "A phase 2 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05466149/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05466149> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-09-27" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/furmonertinib/> ;
  onco:companies <https://onco.cc/companies/allist/> .